Материалы и методы

detinf

ДЕТСКИЕ ИНФЕКЦИИ

CHILDREN INFECTIONS

2072-81072618-8139

Association of Pediatricians and Infection Disease doctors

10.22627/2072-8107-2025-24-2-43-50

detinf-1068

Research Article

ОБЗОР ЛИТЕРАТУРЫ

REVIEW OF THE LITERATURE

Профилактика врожденного токсоплазмоза

Prevention of congenital toxoplasmosis

https://orcid.org/0000-0003-1271-1945

Булгакова

А. Г.

Bulgakova

A. G.

Булгакова Анна Георгиевна, студент 6 курса

Москва

Moscow

anna.okhtyarkina@gmail.com

https://orcid.org/0000-0002-6737-4184

Чуелов

С. Б.

Chuelov

S. B.

Чуелов Сергей Борисович, д.м.н., профессор кафедры инфекционных болезней у детей

Москва

Moscow

chuelovsb@mail.ru

ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова МЗ РФРоссияPirogov Russian National Research Medical University of the Ministry of Health of the Russian FederationRussian Federation

2025

25062025

2424350

2025

Булгакова А.Г., Чуелов С.Б.

Bulgakova A.G., Chuelov S.B.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://detinf.elpub.ru/jour/article/view/1068

Актуальность проблемы врожденного токсоплазмоза обусловлена широкой распространенностью токсоплазмоза в мире, тяжестью течения врожденного токсоплазмоза и возможным развитием резидуальных изменений со стороны центральной нервной системы, органов чувств и других внутренних органов.

Целью работы является обобщение имеющихся в литературе данных об этиологии, эпидемиологии, клинике, диагностике, лечении и профилактике врожденного токсоплазмоза.

Материалы и методы

Материалы и методы. Проведен обзор отечественной и зарубежной литературы за последние 25 лет, в том числе, интернет-ресурсов, включая поисковые системы PubMed, Cochrane Library, Google Scholar.

Заключение

Заключение. Для предупреждения врожденного токсоплазмоза возможно осуществление скрининга как планирующих беременность, так и беременных женщин. В случае подтвержденного инфицирования беременных женщин лечащим врачом может быть рассмотрено проведение медикаментозной профилактики, которая в РФ может осуществляться с использованием макролидного препарата спирамицина. Одним из направлений профилактики является разработка вакцин, среди которых особенно перспективными представляются вакцины на основе наночастиц.

The relevance of the problem of congenital toxoplasmosis is due to the prevalence of toxoplasmosis in the world, the severity of congenital toxoplasmosis and the possible development of residual changes in the central nervous system, sensory organs and other internal organs.

The aim of the work is to summarize the data available in the literature on the etiology, epidemiology, clinical picture, diagnostics, treatment and prevention of congenital toxoplasmosis.

Materials and methods

Materials and methods. A review of domestic and foreign literature over the past 25 years was conducted, including Internet resources, including search engines PubMed, Cochrane Library, Google Scholar.

Conclusion

Conclusion. To prevent congenital toxoplasmosis, it is possible to screen both those planning pregnancy and pregnant women. In case of confirmed infection of pregnant women, the attending physician may consider drug prophylaxis, which in the Russian Federation can be carried out using the macrolide drug spiramycin. One of the areas of prevention is the development of vaccines, among which vaccines based on nanoparticles seem to be especially promising.

Toxoplasma gondiiврожденный токсоплазмозбеременные женщиныноворожденные детипрофилактикавакцины

Toxoplasma gondiicongenital toxoplasmosispregnant womennewbornspreventionvaccines

References1

Kochanowsky JA, Koshy AA. Toxoplasma gondii. Curr Biol. 2018 Jul 23; 28(14):R770—R771. doi: 10.1016/j.cub.2018.05.035.

Innes EA. A brief history and overview of Toxoplasma gondii. Zoonoses Public Health. 2010 Feb; 57(1):1—7. doi: 10.1111/j.1863-2378.2009.01276.x.

Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013; 114:125—45. doi: 10.1016/B978-0-444-53490-3.00008-X.

Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012 Apr; 25(2):264—96. doi: 10.1128/CMR.05013-11.

Błaszkowska J, Góralska K. Parasites and fungi as a threat for prenatal and postnatal human development. Ann Parasitol. 2014; 60(4):225—34.

Maldonado YA, Read JS; COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics. 2017 Feb;139(2):e20163860. doi: 10.15/peds.2016-3860.

Saso A, Bamford A, Grewal K, Noori M, Hatcher J, D'Arco F, Guy E, Lyall H. Fifteen-minute consultation: Management of the infant born to a mother with toxoplasmosis in pregnancy. Arch Dis Child Educ Pract Ed. 2020 Oct; 105(5):262—269. doi: 10.1136/archdischild-2018-316603.

Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 2013 Jul 1; 91(7):501— 8. doi: 10.2471/BLT.12.111732.

Almeida D, Santos-Silva S, Pereira MA, Santos C, Mega C, Coelho C, Nóbrega C, Esteves F, Cruz R, Vala H, Mesquita JR. Prevalence of Toxoplasma gondii Antibodies and Risk Factor Investigation in Portuguese Veterinarians: A Matched Case-Control Study. Pathogens. 2022 Oct 21; 11(10):1217. doi: 10.3390/pathogens11101217.

Deganich M, Boudreaux C, Benmerzouga I. Toxoplasmosis Infection during Pregnancy. Trop Med Infect Dis. 2022 Dec 21; 8(1):3. doi: 10.3390/tropicalmed8010003.

Olarinde O, Sowemimo OA, Chuang TW, Chou CM, Olasanmi SO, Ikotun K, Akinwale OP, Gyang VP, Nwafor T, Olukosi AY, Chang JH, Fan CK. Toxoplasma gondii infection: seroprevalence and associated risk factors for women of childbearing age in Osun State, Nigeria. Pathog Glob Health. 2022 Feb; 116(1):59—65. doi: 10.1080/20477724.2021.1949193.

Yu CP, Chen BC, Chou YC, Hsieh CJ, Lin FH. The epidemiology of patients with toxoplasmosis and its associated risk factors in Taiwan during the 2007—2020 period. PLoS One. 2023 Aug 25; 18(8):e0290769. doi: 10.1371/journal.pone.0290769.

Paquet C, Yudin MH; Society of Obstetricians and Gynaecologists of Canada. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. 2013 Jan; 35(1):78—81. English, French. doi: 10.1016/s1701-2163(15)31053-7.

Dubey JP, Murata FHA, Cerqueira-Cézar CK, Kwok OCH, Villena I. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology. 2021 Oct; 148(12):1406—1416. doi: 10.1017/S0031182021001013.

Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013; 112:1099—101. doi: 10.1016/B978-0-444-52910-7.00028-3.

Losa A, Carvalho I, Sousa B, Ashworth J, Guedes A, Carreira L, Pinho L, Godinho C. Diagnosis of Congenital Toxoplasmosis: Challenges and Management Outcomes. Cureus. 2024 Jan 26; 16(1):e52971. doi: 10.7759/cureus.52971.

Vivacqua DPF, Paz AB, Frota ACC, Penna CRR, Martins MG, Abreu TF, Hofer CB. Antenatal factors related to congenital toxoplasmosis in Rio De Janeiro, Brazil. J Matern Fetal Neonatal Med. 2022 Dec; 35(25):7200— 7206. doi: 10.1080/14767058.2021.1946507.

Remington JS , McLeod R , Thulliez P , Desmonts G . Toxoplasmosis. In: Remington J, Klein G, Wilson C, Baker C, eds. Infectious Disease of the Fetus and Newborn Infant, 6th ed. Philadelphia, PA: W.B. Saunders; 2010:947— 1091.

Burgdorf KS, Trabjerg BB, Pedersen MG, Nissen J, et al. Large-scale study of Toxoplasma and Cytomegalovirus shows an association between infection and serious psychiatric disorders. Brain Behav Immun. 2019 Jul; 79:152—158. doi: 10.1016/j.bbi.2019.01.026.

McGrath JJ, Lim CCW, Saha S. Cat Ownership and Schizophrenia-Related Disorders and Psychotic-Like Experiences: A Systematic Review and MetaAnalysis. Schizophr Bull. 2024 Apr 30; 50(3):489—495. doi: 10.1093/schbul/sbad168.

Fuller Torrey E. The linking of toxoplasmosis and schizophrenia. Folia Parasitol (Praha). 2024 Sep 10; 71:2024.017. doi: 10.14411/fp.2024.016.

Karabulut N, Bilgiç S, Gürok MG, Karaboğa F. Is there any role of latent toxoplasmosis in schizophrenia disease? J Chin Med Assoc. 2015 Sep; 78(9):533—7. doi: 10.1016/j.jcma.2015.06.007.

Karabulut N, Bilgiç S, Gürok MG, Karaboğa F. Is there any role of latent toxoplasmosis in schizophrenia disease? J Chin Med Assoc. 2015 Sep; 78(9):533—7. doi: 10.1016/j.jcma.2015.06.007

Avci ME, Arslan F, Çiftçi Ş, Ekiz A, Tüten A, Yildirim G, Madazli R. Role of spiramycin in prevention of fetal toxoplasmosis. J Matern Fetal Neonatal Med. 2016; 29(13):2073—6. doi:10.3109/14767058.2015.1074998.

Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert Rev Anti Infect Ther. 2012 Jul; 10(7):815—28. doi: 10.1586/eri.12.58.

McLone D, Frim D, Penn R, Swisher CN, et al. Outcomes of hydrocephalus secondary to congenital toxoplasmosis. J Neurosurg Pediatr. 2019 Sep 6; 24(5):601—608. doi: 10.3171/2019.6.PEDS18684.

Hoffmann C. Congenital Toxoplasmosis. In: Rumboldt Z, Castillo M, Huang B, Rossi A, eds. Brain Imaging with MRI and CT: An Image Pattern Approach. Cambridge University Press; 2012:383—384.

Barkovich AJ, Girard N. Fetal brain infections. Childs Nerv Syst. 2003 Aug; 19(7—8):501—7. doi: 10.1007/s00381-003-0763-8.

Codaccioni C, Picone O, Lambert V, Maurice P, et al. Ultrasound features of fetal toxoplasmosis: A contemporary multicenter survey in 88 fetuses. Prenat Diagn. 2020 Dec; 40(13):1741—1752. doi: 10.1002/pd.5756.

Romand S, Chosson M, Franck J, Wallon M, Kieffer F, Kaiser K, Dumon H, Peyron F, Thulliez P, Picot S. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol. 2004 Mar; 190(3):797—802. doi: 10.1016/j.ajog.2003.09.039.

Berrebi A, Bardou M, Bessieres MH, Nowakowska D, et al. Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol. 2007 Nov; 135(1):53—7. doi: 10.1016/j.ejogrb.2006.11.002.

Jacquemard, F. (2000). Clinical aspects of infection during pregnancy. In: Ambroise-Thomas, P., Petersen, P.E. (eds) Congenital toxoplasmosis. Springer, Paris. doi: 10.1007/978-2-8178-0847-5_8

Dhombres F, Friszer S, Maurice P, Gonzales M, Kieffer F, Garel C, Jouannic JM. Prognosis of Fetal Parenchymal Cerebral Lesions without Ventriculomegaly in Congenital Toxoplasmosis Infection. Fetal Diagn Ther. 2017; 41(1):8—14. doi: 10.1159/000445113.

Smith NC, Goulart C, Hayward JA, Kupz A, Miller CM, van Dooren GG. Control of human toxoplasmosis. Int J Parasitol. 2021 Feb; 51(2—3):95— 121. doi: 10.1016/j.ijpara.2020.11.001.

Bollani L, Auriti C, Achille C, Garofoli F, De Rose DU, Meroni V, Salvatori G, Tzialla C. Congenital Toxoplasmosis: The State of the Art. Front Pediatr. 2022 Jul 6; 10:894573. doi: 10.3389/fped.2022.894573.

Melamed, N., Baschat, A., Yinon, Y., Athanasiadis, A., et al. FIGO (International Federation of Gynecology and Obstetrics) initiative on fetal growth: Best practice advice for screening, diagnosis, and management of fetal growth restriction. Int J Gynecol Obstet, 2021; 152:3—57. https://doi.org/10.1002/ijgo.13522

Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect. 2004 Jun; 132(3):541—8. doi: 10.1017/s0950268803001948.

National Collaborating Centre for Women's and Children's Health (UK). Antenatal Care: Routine Care for the Healthy Pregnant Woman. London: RCOG Press; 2008 Mar.

Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol. 2015 Jun; 125(6):1510—1525. doi: 10.1097/01.AOG.0000466430.19823.53.

Клинические рекомендации Российского общества акушеров-гинеколо гов «Нормальная беременность», 2023.

Clinical guidelines of the Russian Society of Obstetricians and Gynecologists «Normal Pregnancy», 2023. (In Russ.)

Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, et al. TOXOGEST Study Group. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018 Oct; 219(4):386.e1— 386.e9. doi: 10.1016/j.ajog.2018.05.031.

Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, Malm G, Salt A, Freeman K, Petersen E, Gilbert RE; European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med. 2010 Oct 12; 7(10):e1000351. doi: 10.1371/journal.pmed.1000351.

Guarch-Ibáñez B, Carreras-Abad C, Frick MA, Blázquez-Gamero D, Baquero-Artigao F, Fuentes I; Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) group; Soler-Palacin P. REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015—2022). The beneficial effects of prenatal treatment on clinical outcomes of infected new borns. PLoS Negl Trop Dis. 2024 Oct 22; 18(10):e0012619. doi: 10.1371/journal.pntd.0012619.

Guarch-Ibáñez B, Carreras-Abad C, Frick MA, Blázquez-Gamero D, Baquero-Artigao F, Fuentes I; Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) group; Soler-Palacin P. REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015—2022). The beneficial effects of prenatal treatment on clinical outcomes of infected new-borns. PLoS Negl Trop Dis. 2024 Oct 22; 18(10):e0012619. doi: 10.1371/journal.pntd.0012619.

Peyron F, L'ollivier C, Mandelbrot L, Wallon M, Piarroux R, Kieffer F, Hadjadj E, Paris L, Garcia-Meric P. Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group. Pathogens. 2019 Feb 18; 8(1):24. doi: 10.3390/pathogens8010024.

De Santis M, Tartaglia S, Apicella M, Visconti D, Noia G, Valentini P, Lanzone A, Santangelo R, Masini L. The prevention of congenital toxoplasmosis using a combination of Spiramycin and Cotrimoxazole: The long-time experience of a tertiary referral centre. Trop Med Int Health. 2024 Aug; 29(8):697—705. doi: 10.1111/tmi.14021.

Durlach R, Freuler C, Messina M, et al. Argentine consensus of congenital toxoplasmosis. Medicina. 2021; 81(2):257—268.

Nelson, John. Nelson’s Pediatric Antimicrobial Therapy. 2023:228—229.

Zhang Y, Li D, Lu S, Zheng B. Toxoplasmosis vaccines: what we have and where to go? NPJ Vaccines. 2022 Oct 31; 7(1):131. doi: 10.1038/s41541-022-00563-0.

Wang JL, Li TT, Elsheikha HM, Chen K, Cong W, Yang WB, Bai MJ, Huang SY, Zhu XQ. Live Attenuated Pru:Δcdpk2 Strain of Toxoplasma gondii Protects Against Acute, Chronic, and Congenital Toxoplasmosis. J Infect Dis. 2018 Jul 24; 218(5):768—777. doi: 10.1093/infdis/jiy211.

Rezaei F, Sarvi S, Sharif M, Hejazi SH, Pagheh AS, Aghayan SA, Daryani A. A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immunization. Microb Pathog. 2019 Jan; 126:172—184. doi: 10.1016/j.micpath.2018.11.003.

Wang JL, Liang QL, Li TT, He JJ, Bai MJ, Cao XZ, Elsheikha HM, Zhu XQ. Toxoplasma gondii tkl1 Deletion Mutant Is a Promising Vaccine against Acute, Chronic, and Congenital Toxoplasmosis in Mice. J Immunol. 2020 Mar 15; 204(6):1562—1570. doi: 10.4049/jimmunol.1900410.

Makino M, Uemura N, Moroda M, Kikumura A, Piao LX, Mohamed RM, Aosai F. Innate immunity in DNA vaccine with Toxoplasma gondii-heat shock protein 70 gene that induces DC activation and Th1 polarization. Vaccine. 2011 Feb 24; 29(10):1899—905. doi: 10.1016/j.vaccine.2010.12.118.

Foroutan M, Ghaffarifar F. Calcium-dependent protein kinases are potential targets for Toxoplasma gondii vaccine. Clin Exp Vaccine Res. 2018 Jan; 7(1):24—36. doi: 10.7774/cevr.2018.7.1.24.

Majidiani H, Soltani S, Ghaffari AD, Sabaghan M, Taghipour A, Foroutan M. In-depth computational analysis of calcium-dependent protein kinase 3 of Toxoplasma gondii provides promising targets for vaccination. Clin Exp Vaccine Res. 2020 Jul; 9(2):146—158. doi:10.7774/cevr.2020.9.2.146.

Ahmed N, Rani NA, Robin TB, Mashrur MN, Shovo MMI, Prome AA, Sultana S, Nazneen Akhand MR. Designing a multi-epitope subunit vaccine against Toxoplasma gondii through reverse vaccinology approach. Mol Biochem Parasitol. 2024 Nov 7; 260:111655. doi: 10.1016/j.molbiopara.2024.111655.

Brito C, Lourenço C, Magalhães J, Reis S, Borges M. Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine against Toxoplasma gondii. Vaccines (Basel). 2023 Mar 25; 11(4):733. doi: 10.3390/vaccines11040733.

The authors declare that there are no conflicts of interest present.